Insiders Keep Buying at Promis Neurosciences Amid 70% Stock Drop, Hinting at Long‑Term Confidence

Insider Buying at Promis Neurosciences Signals Confidence Amid Volatility The latest filing from Williams Eugene, a key shareholder, shows a purchase of 1,316 common shares on 30 Oct 2026 at $3.99 each. The trade brings Eugene’s stake to 13,713 shares, a modest increase but one that occurs against a backdrop of a 70 % yearly decline in the stock. While the price move is minimal, the volume and timing—just before the company’s October 5 option exercise by Ivana Rubino and a November 2 purchase by CSO Neil Cashman—suggest that insiders remain committed to the long‑term prospects of the precision‑medicine platform.

What It Means for Investors Insider buying in a biotech with negative earnings and a trailing P/E of –1.66 can be a bullish signal, especially when combined with the company’s recent pipeline milestones. Eugene’s consistent pattern of acquiring options (e.g., 11,000‑share option on 20 May 2026) and shares (several March purchases averaging $23–24) reflects a strategy of accumulating at lower valuations. For the broader shareholder base, this activity may reduce dilution fears and reinforce the narrative that management believes the current price is undervalued relative to future therapeutic milestones. However, investors should weigh this against the steep 70 % decline and the company’s modest market cap of ~$27 M, which leaves ample room for volatility.

Eugene’s Insider Profile Across the past year, Eugene has executed a mix of option rights and outright purchases. His first major move was a 11,000‑share option on 20 May 2026, followed by a 5,500‑share option the same day, indicating a preference for leveraging cost‑effective entry points. Subsequent March trades—four purchases totaling 6,000 shares—were all at market price, suggesting opportunistic buying when the stock dipped below $25. The October 1,316‑share purchase at $3.99 aligns with his earlier pattern of buying at lower price levels and signals continued belief in the company’s long‑term trajectory.

Broader Insider Activity and Market Sentiment The company’s other insiders, notably CSO Neil Cashman with three trades in November 2026, also demonstrate a willingness to invest during periods of high social media buzz (488 % intensity). Despite a neutral sentiment score of 0, the high buzz indicates heightened discussion around the company’s drug development pipeline. Combined with Eugene’s steady buying, the insider activity paints a cautiously optimistic picture that may temper the market’s negative weekly (-69 %) and monthly (-68 %) declines. For investors, the key takeaway is that insiders are still piling in, which could help anchor the stock as Promis Neurosciences works toward key regulatory milestones.